EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.

Authors: Iphigenie Korakis, Martina Imbimbo, Emiliano Calvo, Sebastian Ochsenreither, Ignacio Ortego, Pascale Tomasini, Kaïssa Ouali, Alexander Desuki, Daniela Di Blasi, Eduard Gasal, Markus Joerger

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2701

Source: Full article

---

Abstract

TPS2701